Clinical efficacy and prognostic factors of salvage liver transplantation for postoperative recurrence of primary liver cancer

王正昕,李瑞东,李建华,陈拓,马震宇,张全保,陶一峰,陈进宏,钦伦秀,陆录,沈丛欢

DOI: https://doi.org/10.3877/cma.j.issn.2095-3232.2021.04.006

2021-01-01

Abstract:Objective:To evaluate the clinical efficacy and to explore the prognostic factors of salvage liver transplantation (SLT) for postoperative recurrence of primary liver cancer.Methods:Clinical data of 273 patients with primary liver cancer who underwent liver transplantation in Huashan Hospital Affiliated to Fudan University from May 2014 to October 2019 were retrospectively analyzed. The informed consents of all patients were obtained and the local ethical committee approval was received. Among them, 252 patients were male and 21 female, aged (51±9) years on average. According to different surgical methods, 196 patients undergoing primary liver transplantation were assigned into the PLT group and 77 patients receiving SLT due to postoperative recurrence after radical resection were allocated into the SLT group. The perioperative conditions and incidence of complications were statistically compared between two groups. Survival analysis was performed by Kaplan-Meier method and Log-rank test. The independent influencing factors of postoperative prognosis of SLT patients were analyzed by Cox proportional hazards regression model.Results:After propensity score matching of baseline data at a ratio of 1:1, 70 patients were assigned into each group. In the SLT group, the operation time was (479±106) min, significantly longer than (438±79) min in the PLT group (t=2.587, P<0.05). The perioperative mortality rate in the SLT group was 11%(8/70), which did not significantly differ from 6%(4/70) in the PLT group (χ2=1.458, P>0.05). The 1-, 3-, 5-year overall survival rates were 85.7%, 75.0%, 63.3% in the SLT group and were 88.3%, 79.0%, 70.3% in the PLT group, respectively. The 1-, 3-, 5-year tumor-free survival rates were 98.4%, 72.2%, 57.1% in the SLT group, and were 92.5%, 74.3%, 54.7% in the PLT group, respectively. The overall survival and tumor-free survival rates did not significantly differ between two groups (χ2=1.627, 0.265; P>0.05). Multivariate analysis demonstrated that AFP >200 μg/L and the maximal tumor diameter >3 cm were the independent risk factors for postoperative overall survival of SLT patients (HR=2.630, 3.082; P<0.05), which were also the independent risk factors for postoperative tumor-free survival (HR=5.965, 3.166; P<0.05).Conclusions:SLT is a safe and reliable treatment for postoperative recurrence of primary liver cancer, which can yield equivalent clinical efficacy to PLT. AFP and tumor diameter are the independent risk factors for the postoperative prognosis of SLT patients.